0001558370-24-013889.txt : 20241030 0001558370-24-013889.hdr.sgml : 20241030 20241030092513 ACCESSION NUMBER: 0001558370-24-013889 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241029 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241030 DATE AS OF CHANGE: 20241030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dogwood Therapeutics, Inc. CENTRAL INDEX KEY: 0001818844 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 854314201 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39811 FILM NUMBER: 241407713 BUSINESS ADDRESS: STREET 1: 44 MILTON AVENUE CITY: ALPHARETTA STATE: GA ZIP: 30009 BUSINESS PHONE: 8666208655 MAIL ADDRESS: STREET 1: 44 MILTON AVENUE CITY: ALPHARETTA STATE: GA ZIP: 30009 FORMER COMPANY: FORMER CONFORMED NAME: Virios Therapeutics, Inc. DATE OF NAME CHANGE: 20201217 FORMER COMPANY: FORMER CONFORMED NAME: Virios Therapeutics, LLC DATE OF NAME CHANGE: 20200721 8-K 1 viri-20241029x8k.htm 8-K
0001818844false00018188442024-10-292024-10-29

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

​

Date of Report (Date of earliest event reported):  October 29, 2024

​

DOGWOOD THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

​

​

​

​

Delaware

001-39811

85-4314201

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

​

​

​

​

44 Milton Avenue

Alpharetta, GA

30009

(Address of principal executive offices)

(Zip Code)

​

Registrant’s telephone number, including area code:  (866) 620-8655

​

(Former name or former address, if changed since last report): Virios Therapeutics, Inc.

​

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001

DWTX

Nasdaq Capital Market

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​

​

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

​

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

​

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

​

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company       ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐

​

​

​

​

Item 8.01 Other Events.

On October 29, 2024, Dogwood Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2), as required by the Hearing Panel’s decision dated June 11, 2024, because the Company’s common stock had a closing bid price of at least $1.00 per share for at least ten consecutive business days, and the matter is now closed.

On October 30, 2024, the Company issued a press release announcing key business developments, which is attached as Exhibit 99.1 to this report.

​

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

​

​

​

​

Exhibit Number

    

Description

99.1

​

104

​

Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

​

​

​

​

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

 

DOGWOOD THERAPEUTICS, INC.

 

 

 

 

By:

/s/ Angela Walsh

 

Name:

Angela Walsh

​

Title:

Chief Financial Officer, Corporate Secretary and Treasurer

October 30, 2024

​

​

​

​

​

3

 EX-99.1 2 viri-20241029xex99d1.htm EX-99.1

Graphic

Exhibit 99.1

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

ATLANTA, Ga., October 30, 2024 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The listing compliance matter is now closed.

Below are some recent key developments in the business.

Key Highlights

•Top-line results from the Bateman Horne Center’s phase 2a study of IMC-2 for the treatment of Long-COVID are expected to be released in mid-November 2024.
•Integration efforts continue following the Company’s acquisition of Pharmagesic (Holdings) Inc. in early October 2024.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms that include a non-opioid analgesic program and an antiviral program. The proprietary non-opioid, Nav 1.7 analgesic program is centered on lead development candidate, Halneuron® which is a voltage-gated sodium channel blocker, a mechanism known to be effective for reducing pain. Halneuron® treatment has demonstrated pain reduction of both general cancer related pain and chemotherapy-induced neuropathic pain (“CINP”).  Interim data from the forthcoming Phase 2 CINP study are expected in 2H 2025.  The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent, celecoxib, for the treatment of illnesses believed to be related to reactivation of previously dormant herpes viruses, including fibromyalgia (“FM”) and Long-COVID (“LC”). Top-line data from an ongoing IMC-2 Phase 2 LC study are expected in mid-November 2024. IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. For more information, please visit www.dwtx.com.

Follow Dogwood Therapeutics

Email Alerts: https://ir.dwtx.com/resources/email-alerts

LinkedIn: https://www.linkedin.com/company/dogwoodther/

Twitter: https://twitter.com/dogwoodther

1

Graphic

Exhibit 99.1

Facebook: https://www.facebook.com/dogwoodther

Forward-Looking Statements

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Contact:

IR@dwtx.com

2

 GRAPHIC 3 viri-20241029xex99d1001.jpg GRAPHIC begin 644 viri-20241029xex99d1001.jpg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viri-20241029.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 viri-20241029_lab.xml EX-101.LAB EX-101.PRE 6 viri-20241029_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Document and Entity Information
Oct. 29, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Oct. 29, 2024
Securities Act File Number 001-39811
Entity Registrant Name DOGWOOD THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 85-4314201
Entity Address, Address Line One 44 Milton Avenue
Entity Address, City or Town Alpharetta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30009
City Area Code 866
Local Phone Number 620-8655
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol DWTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001818844
Amendment Flag false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://virios.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports viri-20241029.xsd viri-20241029_lab.xml viri-20241029_pre.xml viri-20241029x8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "viri-20241029x8k.htm": { "nsprefix": "viri", "nsuri": "http://virios.com/20241029", "dts": { "schema": { "local": [ "viri-20241029.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "viri-20241029_lab.xml" ] }, "presentationLink": { "local": [ "viri-20241029_pre.xml" ] }, "inline": { "local": [ "viri-20241029x8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://virios.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_10_29_2024_To_10_29_2024_13ijdGokfkyQjZghRzyvSA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "viri-20241029x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_29_2024_To_10_29_2024_13ijdGokfkyQjZghRzyvSA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "viri-20241029x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://virios.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001558370-24-013889-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-013889-xbrl.zip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end XML 17 viri-20241029x8k_htm.xml IDEA: XBRL DOCUMENT 0001818844 2024-10-29 2024-10-29 0001818844 false 8-K 2024-10-29 DOGWOOD THERAPEUTICS, INC. DE 001-39811 85-4314201 44 Milton Avenue Alpharetta GA 30009 866 620-8655 Common Stock, par value $0.0001 DWTX NASDAQ false false false false true false